{"id":"NCT00560508","sponsor":"Boehringer Ingelheim","briefTitle":"A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period","officialTitle":"A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-11","primaryCompletion":"2009-11","completion":null,"firstPosted":"2007-11-19","resultsPosted":"2011-02-10","lastUpdate":"2014-07-31"},"enrollment":112,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Pramipexole Immediate Release","otherNames":[]},{"type":"DRUG","name":"Pramipexole Extended Release","otherNames":[]}],"arms":[{"label":"Pramipexole Extended Release","type":"EXPERIMENTAL"},{"label":"Pramipexole Immediate Release","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD on levodopa (L-DOPA) therapy (the double-blind period). The double-blind period will be followed by the open-label 52 week administration of pramipexole ER to evaluate the long term safety and efficacy (the open-label period).","primaryOutcome":{"measure":"Percentage of Participants Who Experienced Adverse Events","timeFrame":"12 weeks","effectByArm":[{"arm":"Pramipexole Extended Release Group (PPX ER)","deltaMin":83.93,"sd":null},{"arm":"Pramipexole Immediate Release Group (PPX IR)","deltaMin":83.93,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":56},"commonTop":["Somnolence","Nasopharyngitis","Constipation","Back pain","Nausea"]}}